1. Home
  2. XTNT vs LUNG Comparison

XTNT vs LUNG Comparison

Compare XTNT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xtant Medical Holdings Inc.

XTNT

Xtant Medical Holdings Inc.

HOLD

Current Price

$0.58

Market Cap

88.7M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.35

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XTNT
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.7M
72.2M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
XTNT
LUNG
Price
$0.58
$1.35
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$1.50
$5.38
AVG Volume (30 Days)
99.1K
680.2K
Earning Date
03-06-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
0.03
N/A
Revenue
$53,337,000.00
$90,497,000.00
Revenue This Year
$15.08
$6.20
Revenue Next Year
N/A
$21.61
P/E Ratio
$19.34
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.34
$1.31
52 Week High
$0.95
$7.97

Technical Indicators

Market Signals
Indicator
XTNT
LUNG
Relative Strength Index (RSI) 47.83 37.62
Support Level $0.55 N/A
Resistance Level $0.68 $2.01
Average True Range (ATR) 0.05 0.17
MACD -0.00 -0.03
Stochastic Oscillator 26.21 5.29

Price Performance

Historical Comparison
XTNT
LUNG

About XTNT Xtant Medical Holdings Inc.

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: